Introduction
============

Glaucoma is among the leading causes of human blindness world wide and continues to pose a clinical challenge yet the sequence of the pathophysiological events that accompany and lead to retinal ganglion cell (RGC) death, the ultimate cause of vision loss in glaucoma, remains incompletely understood. Dogs frequently develop glaucoma spontaneously with advanced age and represent an attractive model for glaucoma research due to the size of their eye, the chronic nature of the disease, and the pathophysiological similarities to glaucoma in humans. In this species ocular exams such as gonioscopy, fundus photography, intraocular pressure (IOP) measurements, slitlamp exams, and indirect ophthalmoscopy are routinely performed and even advanced diagnostic methodologies such as optical coherence tomography, ultrasound, or pattern electroretinogram (pERG) recordings can be conducted \[[@r1],[@r2]\].

An important step toward a better understanding of the pathophysiology of glaucoma is to determine the retinal gene expression profile during the progression of the disease. Several excellent studies describing changes in the global gene expression pattern in the retina and optic nerve of rodent models of glaucoma have been published previously \[[@r3]-[@r7]\].

Here, we examine the gene expression pattern and immune response changes of the retina in healthy eyes and in eyes of dogs with spontaneous glaucoma. Glaucomatous damage in these eyes was typically advanced, allowing insight into the cellular events that occur during late stage glaucoma.

Methods
=======

Canine eyes
-----------

All studies were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Visual Research and are approved by the Iowa State University Committee on Animal Care. Before inclusion in the study all animals were evaluated by a veterinary ophthalmologist (SDG) to rule out the presence of non-related ocular disease. Examinations included slit lamp biomicroscopy, intraocular pressure measurements, indirect ophthalmoscopy, and gonioscopy.

Glaucoma eyes (n=9) were derived from the patient population of the Iowa State University College of Veterinary Medicine Clinics and enucleations were performed with the animal owner's consent to ease pain and suffering. Retinal samples from total of five glaucomatous eyes were used for microarray analysis, while retinal samples of all nine animals were used for PCR analysis. All glaucoma donors were diagnosed with primary glaucoma based on abnormal gonioscopy examination, elevated IOP and absence of other ocular disease. IOP of affected eyes ranged from 30 to 48 mmHg. None of the glaucoma animals used in this study received surgical treatment, but all of them were treated with IOP lowering topical medications.

In addition, eyes from five control dogs without ophthalmic findings were used. These animals were euthanized for reasons unrelated to this study (see [Table 1](#t1){ref-type="table"}).

###### Samples used for gene array analyses.

  **Sample ID**   **Breed/Age**      **IOP (mmHg)**   **Duration**   **Gonioscopy**   **Medications**
  --------------- ------------------ ---------------- -------------- ---------------- ---------------------------
  G1              Shiba Inu, 5y      46               6 months       Closed angle     Latanoprost, brinzolomide
  G2              Shiba Inu, 12y     33               8 months       Closed angle     Latanoprost, brinzolomide
  G3              Dalmatian, 7y      48               1.5 months     Closed angle     Latanoprost, brinzolomide
  G4              Basset Hound, 7y   36               4 months       Closed angle     Latanoprost, brinzolomide
  G5              Basset Hound, 5y   30               6 months       Closed angle     Latanoprost, brinzolomide
  C1              Beagle, 4y         12               n/a            Open angle       n/a
  C2              Beagle, 4y         14               n/a            Open angle       n/a
  C3              Beagle, 4y         12               n/a            Open angle       n/a
  C4              Beagle, 4y         18               n/a            Open angle       n/a
  C5              Beagle, 4y         17               n/a            Open angle       n/a

All glaucoma samples had closed irido-corneal angle appearance during gonioscopy examination, whereas control individuals had open angles and normal IOP. Four additional glaucoma samples were used for RT--PCR analyses.

Gene expression analyses
------------------------

Eyes were dissected and preserved in RNAlater (Ambion, Austin, TX) immediately after enucleation. Samples were then stored at −80 °C until RNA extraction. The neural retina was isolated and total RNA was extracted from the tissue using Qiagen RNeasy minipreps. Samples were treated with RNase free DNase and the integrity of the RNA was evaluated through analysis with a Bioanalyzer (Agilent Technologies, Foster City, CA). RNA was amplified using a T7 RNA polymerase based approach and hybridized to [Affymetrix Canine genome 2.0](http://www.affymetrix.com/estore/browse/products.jsp?navMode=34000&produ) gene chips following standard protocols.

Raw data obtained were normalized using the RMA algorithm. Normalized data were log^2^-transformed and filtered to remove non-expressed genes from the data set. For the purpose of this study, expressed genes are defined as those with corresponding probesets displaying log-expression values above 7.0 in at least 2 samples (either controls or affected). The remaining probesets were analyzed to identify significant expression changes using the Wilcoxon unpaired rank sum test and the significance analysis for microarray ([SAM](http://www-stat.stanford.edu/~tibs/SAM/); Version 3.0; Microsoft Excel Add-In; Stanford University, Palo Alto, CA). Data were analyzed four times using 200 permutations and different seeds values for the random number generator. The delta value was set at 0.53 and a minimum twofold expression change was required. Only genes identified as differentially expressed in all four analyses are presented in this manuscript.

The Database for Annotation, Visualization and Integrated Discovery ([DAVID](http://david.abcc.ncifcrf.gov/)) was used to obtain current Entrez Gene IDs (November, 2007) and the corresponding gene names are used throughout this manuscript. Data have been deposited to the NCBI Gene Expression Omnibus ([GEO](http://www.ncbi.nlm.nih.gov/geo/)) and are available under the accession number [GSE21879](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21879).

Quantitative PCR analyses
-------------------------

Total retinal RNA was extracted from retinas of nine glaucomatous and five control eyes and treated with DNase. These included all eyes used for the microarray studies as well as four additional glaucoma samples. Only one eye from each animal was used. From each sample 500 ng RNA was reverse transcribed in a random primed reaction and 5 ng was used as template in each PCR reaction. DNA amplification was monitored using the dye SYBR Green (Perkin Elmer, Waltham, MA). Data from each sample was obtained in triplicate; amplification controls included wells containing genomic DNA only and those containing no target (water controls). Transcript levels were determined based upon standard curves for each primer pair ([Table 2](#t2){ref-type="table"}). Melt curve analyses were performed following each amplification reaction to ascertain the absence of nonspecific amplification products. Expression values obtained were normalized to transcript levels for ubiquitin C (*UBC*).

###### Oligonucleotide primers used for quantitative PCR analyses.

   **Gene**    **Forward (5′-3′)**        **Reverse (5′-3′)**
  ------------ -------------------------- --------------------------
  *UBC*        TTGTTCGTCTCCGTGCGCTT       TGGATCTTCGCCTTGACGTTCT
  *TNFRSF1A*   TCCAGTGCAATAACTGCAGCCT     ACAACTTCCCGCACTCTGTGTT
  *TNFRSF14*   AGGGACACGATGTGTGAAGACT     AGCATGTGCTTCCCGCTGAA
  *S100A1*     ACCTCAGGTCCAGGCTGACT       AGCTCCTTCTTGCTCAGCTTGT
  *NTF3*       AAGAGGTACGCGGAGCATAA       TTGACAGGCCTGGCTTCTTT
  *NRCAM*      ACGATGTCCCAAATCCTCCGTT     ATAGCCCTGCTTCGTGCATT
  *GMFG*       TGCTGCTGCCACTGGT           TGTGGCACTTCGTACAGCAA
  *CSF1R*      GTTGGTCACCTGCATGTCCATCAT   ACTCCCACTTCTCATTGTAGGGCA

Immunohistochemistry
--------------------

Tissue samples for immunohistochemistry were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned to a thickness of 2 microns. Sections were deparaffinized with heat and xylene and rehydrated by serial rinses in decreasing concentrations of ethanol. Endogenous peroxidase activity was quenched by incubation with 3% H~2~O~2~ for 10 min. Following rinses in potassium phosphate-buffered saline (KPBS), cells were incubated in blocking solution containing 5% normal donkey serum (NDS, 017--000--121; Jackson ImmunoResearch, West Grove, PA), 0.1% BSA (BSA, A9647; Sigma, St. Louis, MO), and 0.04% Triton X-100 for 2 h to eliminate non-specific antibody labeling. Tissue was then incubated in primary polyclonal antibodies overnight at room temperature including: anti-glial fibrillary acid protein (1:2,000; Dako, Carpinteria, CA); anti-CD3 (1:75; Dako); anti-TNF-alpha (1:50; Abcam, Cambridge, MA), anti-TNF-R1 (1:500; Abcam) and anti-TNF R2 (1:25; Abcam). Antibody binding was visualized through incubation with appropriate biotinylated secondary antibodies followed by incubation with avidin-peroxidase conjugate and 3,3′-diaminobenzidine (DAB) with nickel sulfate. Care was taken to maintain identical development times in those cases where labeling intensity was measured. Sections were dehydrated through a graded ethanol series, cleared with xylene, and coverslipped. Negative controls were performed in parallel and included the omission of the primary or secondary antibody. Images of anti-GFAP and anti-CD3 were taken withan Axioplan 2 microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY), equipped with a color camera (AxioCam MRc; Carl Zeiss Meditec, Inc.).

TNF and TNF receptor quantification
-----------------------------------

Four images of the central and peripheral retina were taken for each section using a Nikon Microphot Microscope (Nikon Inc. Garden City, NY) and a 40× oil immersion objective. Central retinal images were obtained within two microscope fields of the optic nerve. Peripheral retinal images were obtained 7--8 microscope fields away from the optic nerve. The microscope settings for tissue stained with a particular antibody were left consistent to eliminate variation from one sample to the next. A blank image that did not contain any tissue was obtained to correct for any slight variations in the slides. Metamorph image analysis software (Ver. 7; Molecular Devices, Sunnyvale CA) was used to quantify the percentage of the retina that was immunoreactive for each antibody. Blank images from the data set were used to correct each slide to account for differences in light illumination. A threshold two standard deviations below the median staining intensity for each group stained with an antibody was determined, the immunoreactivity was pseudocolored and the fraction of the retina labeled was calculated using Metamorph. The immunoreactivity of all retinal layers combined was quantified. Additionally, the combined ganglion cell layer and the inner plexiform layers were analyzed independently. Morphometric data were statistically analyzed using Students *t*-test and Graphpad Prism (ver. 4.0 for Macintosh; Graphpad Software, La Jolla, CA).

Detection of autoantibodies
---------------------------

Initial screening of dog sera was performed using dog retinal proteins that were extracted from a dog retina with 2% octyl glucoside in phosphate/saline buffer (PBS) with proteolytic inhibitors, pH 7.2. The proteins were separated by SDS-gel electrophoresis on a 10% gel and transferred to an Immobilon membrane (Millipore, Bedford, MA). Individual strips containing 10 μg retinal proteins were blocked with 10% normal goat serum, 1% BSA in PBS for 1 h, and then incubated with 1:100 diluted dog serum (1 h) followed by a 1 h incubation with 1:1,000 diluted anti-dog IgG (H and L chain) conjugated to alkaline phosphatase (Sigma, St. Louis, MO). Color reaction was developed by adding the phosphatase substrate until dark bands, appeared in comparison to the positive controls (anti-recoverin antibody diluted 1:50,000, anti-enolase antibody diluted 1:2,000, anti-crystalline-μ antibodies diluted 1:1,000). Western Blots were run and examined in a masked fashion. As a negative control, serum was omitted and only a secondary antibody was applied.

Results
=======

All animals ([Table 1](#t1){ref-type="table"}) received an ocular exam (slitlamp biomicroscopy, intraocular pressure measurements, indirect ophthalmoscopy, and gonioscopy) to rule out the presence of the non-related ocular disease before inclusion in the study. In the majority of canine breeds glaucoma develops through a gradual narrowing and eventual closure of the angle resulting in elevation of IOP and the development of functional deficits. All glaucoma animals used in this study presented with closed irido-corneal angles during gonioscopy examination.

Histology
---------

Histological evaluation of the retina and optic nerve head (ONH) of glaucomatous canine eyes demonstrated that the morphological findings in this species closely resemble those observed in human eyes. As in human glaucoma, the appearance of the ONH in the glaucomatous eye is often characterized by extensive cupping, reorganization of the extracellular matrix and gliotic changes \[[@r2]\]. In the retina of dogs with advanced glaucoma a general thinning of the peripheral retina, associated with extensive loss of cells in the ganglion cell and inner nuclear layers, is evident ([Figure 1](#f1){ref-type="fig"}). Although some loss of nuclei in the outer nuclear layer is discernable, the integrity and organization of the photoreceptor cells is largely maintained. Immunohistochemical analyses demonstrated enhanced expression of glial fibrillary acidic protein (GFAP) in the glaucomatous retina ([Figure 1B](#f1){ref-type="fig"}). GFAP can also be detected in the nerve fiber layer of normal eyes but at much reduced levels ([Figure 1A](#f1){ref-type="fig"}).

![Morphology of the canine retina. Morphology of the peripheral retina in a healthy dog (**A**) and dog with advanced glaucoma (**B**). Glaucomatous changes include dramatic loss of cells in the retinal nerve fiber layer, ganglion cell layer and inner nuclear layer compared to healthy eyes. In the glaucomatous retina GFAP can readily be detected in retinal glial cells (arrows) and indicates extensive gliosis in the nerve fiber layer. GFAP can also be detected in the NFL of normal eyes when extended periods of color development are used. (NFL-nerve fiber layer, RGC-retinal ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer plexiform layer, ONL-outer nuclear layer, OS-Photoreceptor cell outer segments).](mv-v16-2092-f1){#f1}

Gene expression analysis
------------------------

To identify retinal gene expression changes associated with advanced glaucoma, we analyzed the global gene expression patterns in five eyes derived from dogs with glaucoma and from five control animals. As observed in similar analyses of experimental models of glaucoma \[[@r3]-[@r7]\] our analyses indicate significant changes in the transcript levels of a large number of genes. Under the stringent parameters used here (predicted false discovery rate=0.3%) 1,111 probe sets were identified as being differentially expressed between the two groups. Of these, signals from 586 probe sets are significantly reduced in the glaucomatous retina. Further exclusion of probe sets corresponding to unannotated genes results in 362 probe sets representing 275 unique genes ([Table 3](#t3){ref-type="table"}). In addition, 525 probe sets are detected at increased transcript levels in the glaucomatous retina. Of these, 486 probe sets remain after removal of unannotated genes, representing 303 unique genes ([Table 4](#t4){ref-type="table"}).

###### Selected genes detected at decreased levels in the glaucomatous canine retina.

  **Probe Set ID**                                   **Gene**     **Annotation**                                                                              **Glau_avg**   **Cont_avg**   **Fold Change**   **q-value(%)**
  -------------------------------------------------- ------------ ------------------------------------------------------------------------------------------- -------------- -------------- ----------------- ----------------
  **RGC genes**                                                                                                                                                                                               
  CfaAff × 0.30898.1.S1_at                           CALB2        "calbindin 2, (calretinin)"                                                                 7.4            9.5            3.8               0
  CfaAff × 0.29820.1.S1_s\_at                        CIRBP        cold inducible RNA binding protein                                                          9.0            10.3           2.3               0
  CfaAff × 0.27495.1.S1_at                           CPLX3        complexin 3                                                                                 9.1            10.5           2.3               0
  Cfa.12330.1.A1_s\_at                               EBF1         early B-cell factor 1                                                                       5.1            7.2            4.3               0
  Cfa.9181.1.A1_at                                   ELAVL2       "ELAV (embryonic lethal, abnormal vision)-like 2"                                           6.7            9.2            4.6               0
  Cfa.19294.1.S1_s\_at                               ELAVL4       "ELAV (embryonic lethal, abnormal vision)-like 4"                                           6.1            9.2            6.3               0
  \*Cfa.299.1.A1_at                                  FABP3\*      "fatty acid binding protein 3, muscle and heart"                                            7.6            9.4            2.9               0
  Cfa.1153.1.A1_at                                   FKBP1B       "FK506 binding protein 1B, 12.6 kDa"                                                        8.3            10.2           3.5               0
  \*Cfa.5865.1.A1_at                                 KIF5A\*      kinesin family member 5A                                                                    6.7            8.5            2.8               0
  Cfa.10948.1.S1_at                                  LOC610447    Visinin-like protein 1 (VILIP)                                                              7.5            11.5           9.9               0
  \*CfaAff × 0.19019.1.S1_s\_at                      NEFH\*       "neurofilament, heavy polypeptide 200kDa"                                                   6.6            7.9            2.3               0
  Cfa.10952.1.A1_s\_at                               NEFL         "neurofilament, light polypeptide 68kDa"                                                    8.6            12.6           9.3               0
  \*Cfa.10905.1.A1_at                                NEFM\*       "neurofilament, medium polypeptide 150kDa"                                                  8.8            12.9           10.3              0
  \*Cfa.11184.1.A1_s\_at                             NELL2\*      NEL-like 2 (chicken)                                                                        6.9            8.8            3.7               0
  Cfa.9043.1.A1_at                                   NRG1         neuregulin 1                                                                                6.3            7.4            2.2               0
  CfaAff × 0.14934.1.S1_at                           NRN1         neuritin 1                                                                                  6.6            9.2            5.5               0
  Cfa.12391.1.A1_s\_at                               RBPMS        RNA binding protein with multiple splicing                                                  6.8            7.7            2.0               0
  \*CfaAff × 0.11569.1.S1_s\_at                      SCN1B\*      "sodium channel, voltage-gated, type I, beta"                                               6.0            7.4            2.7               0
  \*CfaAff × 0.13307.1.S1_s\_at                      STMN2\*      stathmin-like 2                                                                             8.9            10.4           3.1               0
  \*Cfa.4489.1.S1_at                                 UCHL1\*      ubiquitin carboxyl-terminal esterase L1                                                     11.4           12.7           2.6               0
  **Synapse and Synaptic Transmission**                                                                                                                                                                       
  \*CfaAff × 0.21696.1.S1_at                         ACHE\*       acetylcholinesterase                                                                        6.0            7.4            2.4               0
  CfaAff × 0.11508.1.S1_s\_at                        CADPS        Ca^2+^dependent secretion activator                                                         8.6            10.4           3.3               0
  CfaAff × 0.18352.1.S1_s\_at                        CPNE6        copine VI (neuronal)                                                                        6.8            7.9            2.1               0
  Cfa.9427.1.A1_at                                   CRH          corticotropin releasing hormone                                                             6.5            8.6            3.8               0
  Cfa.21295.1.S1_s\_at                               DRD1IP       dopamine receptor D1 interacting protein                                                    7.3            9.5            4.6               0
  CfaAff × 0.4606.1.S1_at                            GABBR2       "gamma-aminobutyric acid (GABA) B receptor, 2"                                              6.4            7.5            2.1               0
  CfaAff × 0.26365.1.S1_at                           GABRA1       "gamma-aminobutyric acid (GABA) A receptor, alpha 1"                                        5.4            7.7            4.3               0
  \*Cfa.11206.1.A1_at                                GABRB3\*     "gamma-aminobutyric acid (GABA) A receptor, beta 3"                                         6.8            9.5            5.4               0
  CfaAff × 0.26360.1.S1_s\_at                        GABRG2       "gamma-aminobutyric acid (GABA) A receptor, gamma 2"                                        6.3            8.4            4.1               0
  CfaAff × 0.5585.1.S1_s\_at                         GABRR1       "gamma-aminobutyric acid (GABA) receptor, rho 1"                                            6.3            8.8            5.2               0
  \*Cfa.1206.2.A1_s\_at                              GAD1\*       "glutamate decarboxylase 1 (brain, 67kDa)"                                                  5.7            8.1            4.4               0
  \*CfaAff × 0.13687.1.S1_at                         GRIA2\*      "glutamate receptor, ionotropic, AMPA 2"                                                    7.4            9.1            3.4               0
  CfaAff × 0.22871.1.S1_at                           GRIA4        "glutamate receptor, ionotrophic, AMPA 4"                                                   6.2            7.6            2.5               0
  CfaAff × 0.3513.1.S1_at                            GRM8         "glutamate receptor, metabotropic 8"                                                        5.2            7.8            5.5               0
  CfaAff × 0.4263.1.S1_s\_at                         ICA1         "islet cell autoantigen 1, 69kDa"                                                           6.1            7.6            2.7               0
  Cfa.9545.1.A1_at                                   NOVA1        neuro-oncological ventral antigen 1                                                         7.0            8.2            2.3               0
  CfaAff × 0.28644.1.S1_at                           RAB33A       "RAB33A, member RAS oncogene family"                                                        7.1            8.2            2.1               0
  CfaAff × 0.11242.1.S1_s\_at                        SYNPR        synaptoporin                                                                                6.0            8.2            4.1               0
  CfaAff × 0.18684.1.S1_s\_at                        SYT14        synaptotagmin XIV                                                                           6.5            7.8            2.6               0
  CfaAff × 0.27070.1.S1_at                           SYT4         synaptotagmin IV                                                                            5.5            7.3            3.7               0
  Cfa.4050.1.A1_a\_at                                TAC1         "tachykinin, precursor 1"                                                                   6.1            8.2            3.4               0
  **Phototransduction**                                                                                                                                                                                       
  CfaAff × 0.25681.1.S1_at                           ARR3         "arrestin 3, retinal (X-arrestin)"                                                          10.3           12.9           2.1               0
  Cfa.3480.1.A1_s\_at                                GNGT2        "guanine nucleotide binding protein, gamma"                                                 10.3           12.3           2.4               0.064323389
  CfaAff × 0.3367.1.S1_at                            OPN1SW       "opsin 1, short-wave-sensitive"                                                             7.6            10.6           3.5               0.064323389
  CfaAff × 0.12695.1.S1_s\_at                        PDE6C        cGMP-specific phosphodiesterase 6C                                                          7.1            8.6            2.0               0.064323389
  **Synucleins**                                                                                                                                                                                              
  \*CfaAff × 0.15497.1.S1_s\_at                      SNCA\*       "synuclein, alpha "                                                                         5.8            7.4            2.9               0
  \*CfaAff × 0.25469.1.S1_s\_at                      SNCB\*       "synuclein, beta"                                                                           7.1            8.5            2.3               0
  CfaAff × 0.24686.1.S1_at                           SNCG         "synuclein, gamma"                                                                          5.9            8.5            5.1               0
  **Growth Factors**                                                                                                                                                                                          
  Cfa.19396.1.S1_s\_at                               FGF12        fibroblast growth factor 12                                                                 5.5            7.0            2.9               0
  \*CfaAff × 0.9858.1.S1_s\_at                       FGF14\*      fibroblast growth factor 14                                                                 6.8            8.0            2.2               0
  \*Cfa.3888.1.S1_at                                 IGF1\*       insulin-like growth factor 1 (somatomedin C)                                                4.8            6.5            3.5               0
  CfaAff × 0.2203.1.S1_at                            IL5          "interleukin 5 (colony-stimulating factor, eosinophil)"                                     5.0            7.2            4.4               0
  \*Cfa.4064.1.A1_at                                 PTN\*        pleiotrophin (neurite growth-promoting factor 1)                                            6.4            8.4            4.5               0
  **Cell Adhesion**                                                                                                                                                                                           
  CfaAff × 0.14553.1.S1_at                           AMIGO2       adhesion molecule with Ig-like domain 2                                                     6.4            8.1            3.2               0
  CfaAff × 0.29067.1.S1_at                           CDH12        "cadherin 12, type 2 (N-cadherin 2)"                                                        6.1            7.7            2.9               0
  CfaAff × 0.29091.1.S1_at                           CDH18        "cadherin 18, type 2"                                                                       5.6            7.4            3.4               0
  CfaAff × 0.1039.1.S1_at                            CDH7         "cadherin 7, type 2"                                                                        7.4            8.6            2.4               0
  Cfa.9512.1.A1_at                                   CTNNA2       "catenin (cadherin-associated protein), alpha 2"                                            7.3            8.8            3.1               0
  Cfa.3718.1.S1_s\_at                                DSC2         desmocollin 2                                                                               6.1            7.4            3.0               0
  CfaAff × 0.13441.1.S1_s\_at                        EDIL3        EGF-like repeats and discoidin I-like domains 3                                             5.6            7.3            2.7               0
  Cfa.2219.1.A1_at                                   ITGA6        "integrin, alpha 6"                                                                         7.5            8.3            2.2               0
  \*CfaAff × 0.8342.1.S1_at                          PCDH9\*      protocadherin 9                                                                             6.4            7.7            2.5               0
  Cfa.9146.1.A1_at                                   PCDHAC2      "protocadherin alpha subfamily C, 2"                                                        7.0            8.8            3.3               0
  Cfa.9467.1.A1_at                                   RELN         reelin                                                                                      8.4            9.6            2.5               0
  **Calcium Binding**                                                                                                                                                                                         
  \*Cfa.7840.1.A1_at                                 CABP5\*      calcium binding protein 5                                                                   8.6            11.2           4.7               0
  \*CfaAff × 0.14235.1.S1_s\_at                      CALB1\*      "calbindin 1, 28kDa"                                                                        6.3            10.0           6.8               0
  Cfa.4168.2.S1_s\_at                                CALM1        "calmodulin 1 (phosphorylase kinase, delta)"                                                10.2           11.2           2.4               0
  Cfa.20415.1.S1_at                                  HPCA         hippocalcin                                                                                 7.4            8.9            2.6               0
  Cfa.10160.1.S1_at                                  PPP3CA       "protein phosphatase 3, catalytic subunit, alpha isoform"                                   9.3            10.2           2.1               0
  Cfa.10339.1.S1_at                                  PPP3R1       "protein phosphatase 3, regulatory subunit B, alpha isoform"                                8.3            9.5            2.4               0
  Cfa.10159.1.S1_at                                  PRKCB1       "protein kinase C, beta 1"                                                                  8.0            9.8            4.3               0
  \*Cfa.20981.1.S1_s\_at                             PVALB\*      parvalbumin                                                                                 7.7            12.1           12.0              0
  **Calcium Channels**                                                                                                                                                                                        
  \*Cfa.1728.1.A1_s\_at                              CACNA2D3\*   "Ca channel, voltage-dependent, alpha 2/delta 3 subunit"                                    6.3            8.5            4.2               0
  Cfa.1210.1.S1_at                                   CACNB3       "Ca channel, voltage-dependent, beta 3 subunit"                                             7.2            8.3            2.6               0
  Cfa.269.1.A1_at                                    RYR2         ryanodine receptor 2                                                                        5.3            7.0            3.2               0
  CfaAff × 0.7090.1.S1_s\_at                         TRPC3        "transient receptor potential cation channel, subfamily C, member 3"                        5.5            7.6            4.4               0
  \*CfaAff × 0.16161.1.S1_s\_at                      TRPM1\*      "transient receptor potential cation channel, subfamily M, member 1"                        8.0            9.8            4.6               0
  **Neuronal Development**                                                                                                                                                                                    
  \*Cfa.9271.1.A1_at                                 CA10\*       carbonic anhydrase X                                                                        7.3            10.0           6.1               0
  Cfa.10284.1.S1_s\_at                               CRMP1        collapsin response mediator protein 1                                                       6.1            7.1            2.1               0
  CfaAff × 0.16492.1.S1_at                           DNER         delta/notch-like EGF repeat containing                                                      8.8            9.7            2.0               0
  Cfa.19360.1.S1_s\_at                               GNAO1        "guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O"   8.9            10.8           3.8               0
  Cfa.7236.1.A1_s\_at                                NRXN1        neurexin 1                                                                                  7.1            9.4            4.2               0
  \*Cfa.10306.1.S1_at                                OLFM1\*      olfactomedin 1                                                                              8.6            10.0           2.5               0
  CfaAff × 0.30602.1.S1_at                           OLFM3        olfactomedin 3                                                                              5.8            7.1            2.9               0
  \*Cfa.9934.1.A1_at                                 PCP4\*       Purkinje cell protein 4                                                                     9.6            13.0           8.9               0
  Cfa.15689.1.A1_at                                  PHYH         phytanoyl-CoA 2-hydroxylase                                                                 7.1            9.2            4.3               0
  CfaAff × 0.12766.1.S1_at                           ROBO2        "roundabout, axon guidance receptor, homolog 2"                                             5.8            7.8            4.2               0
  \*CfaAff × 0.22493.1.S1_s\_at                      SERPINI1\*   "serpin peptidase inhibitor, clade I, member 1"                                             10.0           11.8           3.0               0
  \*Cfa.10644.1.A1_at                                SH3GL3\*     SH3-domain GRB2-like 3                                                                      6.8            9.0            5.2               0
  \*Cfa.1224.1.S1_at                                 TAGLN3\*     transgelin 3                                                                                9.2            11.9           4.9               0
  Cfa.174.1.S1_s\_at                                 TFAP2B       transcription factor AP-2 beta                                                              6.9            9.6            4.4               0
  **Transcription Factors**                                                                                                                                                                                   
  CfaAff × 0.12012.1.S1_at                           GTF2H3       "general transcription factor IIH, polypeptide 3, 34kDa"                                    5.8            6.8            2.0               0.126704939
  CfaAff × 0.28228.1.S1_at                           ISL1         ISL LIM homeobox 1                                                                          6.2            7.6            2.9               0
  CfaAff × 0.5793.1.S1_s\_at                         MYT1L        myelin transcription factor 1-like                                                          5.5            6.8            2.4               0
  CfaAff × 0.25541.1.S1_s\_at                        RORA         RAR-related orphan receptor A                                                               5.6            6.8            2.1               0.064323389
  Cfa.5127.1.A1_s\_at                                RUNX1T1      runt-related transcription factor 1                                                         6.6            8.1            2.8               0
  \*CfaAff × 0.20645.1.S1_at                         RXRG\*       "retinoid X receptor, gamma"                                                                7.0            8.1            2.0               0
  **G-protein coupled receptor protein signaling**                                                                                                                                                            
  Cfa.11087.1.A1_s\_at                               BAI3         brain-specific angiogenesis inhibitor 3                                                     7.2            8.9            3.3               0
  \*CfaAff × 0.8825.1.S1_s\_at                       CCK\*        cholecystokinin                                                                             5.4            7.2            2.7               0.126704939
  Cfa.3870.1.A1_at                                   GAL          galanin prepropeptide                                                                       5.6            8.0            5.5               0
  \*Cfa.3177.1.S1_at                                 GNAI1\*      "guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1"   9.8            11.2           2.8               0
  \*Cfa.10270.2.A1_at                                GNG3\*       "guanine nucleotide binding protein (G protein), gamma 3"                                   7.5            9.5            3.6               0
  CfaAff × 0.5919.1.S1_at                            GPR85        G protein-coupled receptor 85                                                               7.0            9.0            4.2               0
  CfaAff × 0.4269.1.S1_at                            NXPH1        neurexophilin 1                                                                             6.2            8.9            5.4               0
  \*Cfa.9688.1.A1_at                                 NXPH2\*      neurexophilin 2                                                                             5.8            7.2            2.6               0
  Cfa.1416.1.A1_at                                   PENK         proenkephalin                                                                               5.7            7.4            3.2               0
  Cfa.11233.1.A1_at                                  SSTR2        somatostatin receptor 2                                                                     5.9            7.0            2.3               0.064323389
  **Cytoskeleton**                                                                                                                                                                                            
  CfaAff × 0.5843.1.S1_s\_at                         ELMO1        engulfment and cell motility 1                                                              6.8            8.8            5.0               0
  Cfa.6416.1.A1_at                                   SGCG         "sarcoglycan, gamma"                                                                        6.0            7.0            2.1               0
  \*Cfa.11292.1.A1_at                                TMOD1\*      tropomodulin 1                                                                              6.9            8.8            3.0               0
  \*Cfa.10164.1.S1_at                                TUBA4A\*     "tubulin, alpha 4a"                                                                         7.1            9.8            4.9               0
  \*Cfa.11276.1.S1_s\_at                             TUBB2A\*     "tubulin, beta 2A"                                                                          11.1           12.9           3.3               0

Asterisks indicate that elevated decreased levels for this gene were detected by more than one probe set. Expression levels and fold change values are given as log^2^ units.

###### Selected genes detected at increased levels in the glaucomatous canine retina.

  **Probe Set ID**                                                          **Gene**      **Annotation**                                                                          **Glau_avg**   **Cont_avg**   **Fold change**   **q-value (%)**
  ------------------------------------------------------------------------- ------------- --------------------------------------------------------------------------------------- -------------- -------------- ----------------- -----------------
  **Complement components**                                                                                                                                                                                                       
  \*Cfa.1379.1.S1_at                                                        C1QA\*        "complement component 1, q subcomponent, A chain"                                       11.8           9.6            4.3               0
  Cfa.16857.1.S1_at                                                         C1QB          "complement component 1, q subcomponent, B chain"                                       10.9           8.1            5.5               0
  \*Cfa.10921.1.S1_at                                                       C1QC\*        "complement component 1, q subcomponent, C chain"                                       11.4           8.0            9.3               0
  \*Cfa.21168.1.S1_s\_at                                                    C1R\*         "complement component 1, r subcomponent"                                                8.0            6.3            2.9               0
  \*Cfa.10821.1.A1_s\_at                                                    C1S\*         "complement component 1, s subcomponent"                                                12.3           10.5           3.5               0
  \*Cfa.12240.1.A1_at                                                       C3\*          complement component 3                                                                  13.7           9.1            21.8              0
  CfaAff × 0.21480.1.S1_at                                                  C3AR1\*       complement component 3a receptor 1                                                      6.9            5.6            2.0               0
  \*Cfa.14267.1.S1_at                                                       CFB\*         complement factor B                                                                     11.0           9.3            2.9               0
  \*Cfa.14495.2.S1_at                                                       CFI\*         complement factor I                                                                     10.6           8.8            3.2               0
  \*Cfa.21548.1.S1_s\_at                                                    LOC481722\*   similar to Complement C4 precursor                                                      8.6            6.3            4.7               0
  \*Cfa.3117.1.S1_at                                                        SERPING1\*    "serpin peptidase inhibitor, clade G (C1 inhibitor)"                                    12.5           10.3           4.2               0
  CfaAff × 0.24815.1.S1_at                                                  TLR1          toll-like receptor 1                                                                    7.7            6.5            2.5               0.181332902
  CfaAff × 0.11983.1.S1_at                                                  TLR3          toll-like receptor 3                                                                    7.9            6.4            2.2               0.181332902
  CfaAff × 0.18172.1.S1_at                                                  TLR7          Toll-like receptor 7                                                                    7.1            5.8            2.4               0
  **Acute Phase Proteins**                                                                                                                                                                                                        
  CfaAff × 0.23392.1.S1_x\_at                                               SAA           serum amyloid A protein                                                                 7.2            5.8            3.8               0
  \*Cfa.3173.2.A1_a\_at                                                     SAA1\*        serum amyloid A1                                                                        7.9            4.8            20.1              0
  \*Cfa.3173.2.A1_a\_at                                                     SAA2\*        serum amyloid A2                                                                        7.9            4.8            20.1              0
  Cfa.5989.1.A1_s\_at                                                       SERPINA1      "serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1"   7.9            6.5            2.2               0
  \*Cfa.14503.1.A1_at                                                       SERPINA3\*    "serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3"   9.7            7.2            5.7               0
  \*Cfa.5199.1.A1_at                                                        STAT3\*       signal transducer and activator of transcription 3                                      9.6            8.3            2.4               0
  **Apoptosis**                                                                                                                                                                                                                   
  CfaAff × 0.7867.1.S1_s\_at                                                APOE          apolipoprotein E                                                                        11.8           9.5            4.4               0
  Cfa.110.1.S1_s\_at                                                        BCL2          B-cell CLL/lymphoma 2                                                                   9.1            7.7            2.6               0
  \*Cfa.21056.1.S1_at                                                       BCL2A1\*      BCL2-related protein A1                                                                 8.3            6.2            5.4               0
  Cfa.3589.1.S1_s\_at                                                       CASP4         "caspase 4, apoptosis-related cysteine peptidase"                                       8.4            6.3            3.7               0
  Cfa.3851.1.S1_s\_at                                                       CCL2          chemokine (C-C motif) ligand 2                                                          7.8            6.2            4.7               0
  CfaAff × 0.29633.1.S1_s\_at                                               GADD45B       "growth arrest and DNA-damage-inducible, beta"                                          9.1            7.3            3.2               0
  CfaAff × 0.16351.1.S1_s\_at                                               IFIH1         interferon induced with helicase C domain 1                                             7.9            6.7            2.3               0
  Cfa.40.1.S1_s\_at                                                         IL18          interleukin 18 (interferon-gamma-inducing factor)                                       6.9            5.5            2.5               0
  Cfa.13715.1.A1_at                                                         LOC479458     similar to caspase 12 (mouse)                                                           7.0            4.8            4.4               0
  CfaAff × 0.15920.1.S1_s\_at                                               MX1           "myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)"    11.0           9.7            2.2               0
  CfaAff × 0.23506.1.S1_at                                                  NTF3          neurotrophin 3                                                                          7.2            5.9            3.3               0
  \*Cfa.9240.1.S1_at                                                        SPP1\*        secreted phosphoprotein 1 (osteopontin)                                                 9.7            6.3            9.2               0
  \*Cfa.18084.1.S1_s\_at                                                    STAT1\*       signal transducer and activator of transcription 1                                      7.8            6.2            3.0               0
  Cfa.18359.1.S1_at                                                         STK17B        serine/threonine kinase 17b                                                             7.9            6.9            2.2               0
  \*CfaAff × 0.12369.1.S1_s\_at                                             SULF1\*       sulfatase 1                                                                             8.8            7.5            2.1               0
  Cfa.6225.1.A1_at                                                          TNFRSF14      "tumor necrosis factor receptor superfamily, member 14"                                 8.3            7.1            2.2               0
  CfaAff × 0.23380.1.S1_s\_at                                               TNFRSF1A      "tumor necrosis factor receptor superfamily, member 1A"                                 7.4            6.3            2.1               0
  **Protein degradation**                                                                                                                                                                                                         
  \*CfaAff × 0.14173.1.S1_s\_at                                             CTSC\*        cathepsin C                                                                             11.4           8.2            7.9               0
  \*Cfa.2521.1.S1_at                                                        CTSH\*        cathepsin H                                                                             12.0           10.0           3.5               0
  \*Cfa.1661.1.S1_at                                                        CTSS\*        cathepsin S                                                                             11.5           9.1            4.6               0
  CfaAff × 0.18934.1.S1_at                                                  CTSZ          cathepsin Z                                                                             8.3            6.9            2.4               0
  Cfa.4392.1.S1_at                                                          DNASE2        "deoxyribonuclease II, lysosomal"                                                       9.8            8.5            2.2               0
  Cfa.10080.1.A1_at                                                         LAMP2         lysosomal-associated membrane protein 2                                                 9.8            8.5            2.0               0.181332902
  \*Cfa.9004.1.S1_at                                                        LAPTM5\*      lysosomal associated multispanning membrane protein 5                                   10.4           8.3            3.9               0
  \*Cfa.11935.1.A1_at                                                       LGMN\*        legumain                                                                                9.1            8.1            2.1               0
  \*Cfa.797.1.S1_at                                                         LGALS3        "lectin, galactoside-binding, soluble, 3"                                               11.9           10.5           2.4               0
  CfaAff × 0.9252.1.S1_at                                                   LGALS3BP      "lectin, galactoside-binding, soluble, 3 binding protein"                               7.9            6.7            2.3               0
  \*Cfa.15305.1.S1_at                                                       LYZ\*         lysozyme                                                                                10.5           7.9            5.2               0
  CfaAff × 0.7537.1.S1_at                                                   PRSS23        "protease, serine, 23"                                                                  9.3            8.1            2.1               0
  \*Cfa.12298.1.A1_a\_at                                                    PSMB8\*       "proteasome subunit, beta type, 8"                                                      8.9            7.2            3.6               0
  **Antigen processing/presentation**                                                                                                                                                                                             
  CfaAff × 0.21053.1.S1_s\_at                                               B2M           beta-2-microglobulin                                                                    13.1           11.9           2.2               0
  \*Cfa.20996.1.S1_at                                                       DLA-12\*      MHC class I DLA-12                                                                      12.2           10.3           3.7               0
  CfaAff × 0.1704.1.S1_s\_at                                                DLA-64        MHC class I DLA-64                                                                      8.7            6.2            5.6               0
  \*Cfa.14528.1.A1_at                                                       DLA-79\*      MHC class Ib                                                                            10.2           8.3            3.8               0
  \*Cfa.280.1.S1_s\_at                                                      dla88\*       MHC class I DLA-88                                                                      13.6           12.2           2.6               0
  \*Cfa.182.1.S1_s\_at                                                      DLA-DQA1\*    "major histocompatibility complex, class II, DQ alpha 1"                                7.7            5.4            5.1               0
  CfaAff × 0.2152.1.S1_s\_at                                                DLA-DQB1      "major histocompatibility complex, class II, DQ beta 1"                                 10.4           7.3            9.0               0
  \*Cfa.6456.1.S1_at                                                        DLA-DRA1\*    MHC class II DR alpha chain                                                             12.0           9.3            6.2               0
  Cfa.181.1.S1_at                                                           DLA-DRB1      MHC class II DLA DRB1 beta chain                                                        12.3           9.5            6.1               0
  Cfa.173.1.A1_s\_at                                                        FCGR1A        "Fc fragment of IgG, high affinity Ia, receptor (CD64)"                                 8.9            6.6            4.5               0
  \*Cfa.21258.1.S1_at                                                       FCGR3A\*      "Fc fragment of IgG, low affinity IIIa, receptor (CD16a)"                               8.0            5.2            6.9               0
  \*Cfa.17806.1.S1_at                                                       FCGRT\*       "Fc fragment of IgG, receptor, transporter, alpha"                                      9.9            8.7            2.3               0
  \*Cfa.18297.1.S1_at                                                       HLA-DMA\*     "major histocompatibility complex, class II, DM alpha"                                  9.2            7.2            3.9               0
  **Inflammation**                                                                                                                                                                                                                
  CfaAff × 0.11797.1.S1_s\_at                                               ACOX2         "acyl-Coenzyme A oxidase 2, branched chain"                                             8.7            7.0            2.7               0
  Cfa.14366.1.S1_s\_at                                                      AIF1          allograft inflammatory factor 1                                                         8.6            7.3            2.4               0
  \*Cfa.10210.1.S1_at                                                       ALOX5AP\*     arachidonate 5-lipoxygenase-activating protein                                          9.7            8.1            2.8               0
  \*Cfa.19174.1.S1_s\_at                                                    CD163\*       CD163 molecule                                                                          6.4            5.0            2.2               0
  \*Cfa.6017.1.S1_at                                                        CYBB\*        "cytochrome b-245, beta polypeptide"                                                    8.4            6.0            5.3               0
  Cfa.3634.1.S1_at                                                          ITGB2         "integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)"                    8.1            6.8            2.2               0
  Cfa.12422.1.A1_at                                                         MGST2         microsomal glutathione S-transferase 2                                                  6.5            5.3            2.5               0
  CfaAff × 0.9427.1.S1_at                                                   TNFAIP6       "tumor necrosis factor, alpha-induced protein 6"                                        10.5           9.0            2.8               0
  \*CfaAff × 0.3283.1.S1_s\_at                                              TREM2\*       triggering receptor expressed on myeloid cells 2                                        7.8            6.4            2.8               0
  **T and B cell proteins**                                                                                                                                                                                                       
  \*Cfa.14560.1.S1_at                                                       CD48\*        CD48 molecule                                                                           7.8            5.9            4.0               0
  Cfa.3629.2.S1_s\_at                                                       CD86          CD86 molecule                                                                           9.9            8.0            3.8               0
  Cfa.12433.1.A1_at                                                         CD99          CD99 molecule                                                                           10.2           8.9            2.0               0
  CfaAff × 0.20171.1.S1_s\_at                                               FCRLA         Fc receptor-like A                                                                      8.5            5.3            8.4               0
  CfaAff × 0.11449.1.S1_at                                                  ID1           inhibitor of DNA binding 1                                                              8.9            7.9            2.1               0
  \*Cfa.64.1.S1_at                                                          ID3\*         inhibitor of DNA binding 3                                                              10.3           8.7            2.9               0
  Cfa.4556.2.S1_s\_at                                                       IGHAC         IgA heavy chain constant region                                                         7.1            5.6            3.7               0.181332902
  Cfa.4556.3.A1_s\_at                                                       LOC607467     Ig heavy chain V-III region VH26 precursor                                              7.9            5.8            5.7               0.181332902
  Cfa.15473.1.A1_at                                                         LY86          lymphocyte antigen 86                                                                   7.8            6.6            2.0               0
  \*Cfa.19790.1.S1_at                                                       NFAT5\*       "nuclear factor of activated T-cells 5, tonicity-responsive"                            9.3            8.2            2.1               0
  Cfa.17809.1.S1_s\_at                                                      PTPRC         "protein tyrosine phosphatase, receptor type, C"                                        6.3            5.0            2.4               0
  Cfa.11351.1.A1_at                                                         TCIRG1        "T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3"          8.7            7.5            2.2               0
  **Growth Factors, growth factor binding proteins, and their receptors**                                                                                                                                                         
  \*Cfa.17361.1.S1_s\_at                                                    CSF1R\*       colony stimulating factor 1 receptor                                                    9.6            6.4            11.1              0
  CfaAff × 0.9754.1.S1_s\_at                                                LTBP1         latent transforming growth factor beta binding protein 1                                7.3            5.9            2.5               0
  Cfa.18699.1.S1_s\_at                                                      LTBP3         latent transforming growth factor beta binding protein 3                                8.5            7.3            2.2               0
  Cfa.10765.1.S1_s\_at                                                      PDGFRA        "platelet-derived growth factor receptor, alpha polypeptide"                            8.4            7.3            2.2               0
  CfaAff × 0.2176.1.S1_at                                                   TNFRSF11B     "tumor necrosis factor receptor superfamily, member 11b"                                8.0            6.4            2.3               0
  **Chemokine ligands and receptors**                                                                                                                                                                                             
  CfaAff × 0.21302.1.S1_s\_at                                               CCR5          chemokine (C-C motif) receptor 5                                                        7.4            5.9            3.4               0.181332902
  \*Cfa.16590.1.S1_s\_at                                                    CXCL10\*      chemokine (C-X-C motif) ligand 10                                                       6.9            4.7            9.5               0.181332902
  \*Cfa.20779.1.S1_at                                                       CXCL12\*      chemokine (C-X-C motif) ligand 12                                                       8.5            7.1            4.0               0
  CfaAff × 0.24352.1.S1_at                                                  CXCL16        chemokine (C-X-C motif) ligand 16                                                       8.0            5.9            4.7               0
  Cfa.14516.1.S1_at                                                         IL18BP        interleukin 18 binding protein                                                          9.4            7.8            3.4               0
  **Extracellular Matrix Constituents**                                                                                                                                                                                           
  Cfa.10374.1.A1_at                                                         COL12A1       "collagen, type XII, alpha 1"                                                           6.8            4.8            4.2               0
  \*Cfa.6936.1.A1_at                                                        COMP\*        cartilage oligomeric matrix protein                                                     7.7            6.6            2.5               0
  \*Cfa.15083.1.S1_at                                                       EFEMP1\*      fibulin 3                                                                               8.7            7.6            2.0               0
  \*Cfa.4189.1.A1_at                                                        EFEMP2\*      fibulin 4                                                                               11.4           10.2           2.2               0
  \*Cfa.19661.1.S1_s\_at                                                    FBLN5\*       fibulin 5                                                                               8.0            6.5            2.2               0
  \*Cfa.5998.1.A1_x\_at                                                     FGG\*         fibrinogen gamma chain                                                                  8.0            6.7            3.4               0
  CfaAff × 0.1090.1.S1_at                                                   MMP19         matrix metallopeptidase 19                                                              7.1            5.6            2.3               0
  Cfa.19828.1.S1_at                                                         LOC475881     Neuronal cell adhesion molecule precursor (Nr-CAM)                                      9.5            8.5            2.0               0
  **Misc. Molecules**                                                                                                                                                                                                             
  CfaAff × 0.20132.1.S1_at                                                  ACE           angiotensin I converting enzyme 1                                                       9.7            7.4            4.7               0
  Cfa.3982.1.A1_at                                                          AGT           angiotensinogen                                                                         8.0            6.6            3.2               0
  \*Cfa.2878.1.A1_s\_at                                                     CP\*          ceruloplasmin (ferroxidase)                                                             11.0           7.6            10.4              0
  \*Cfa.19821.1.S1_s\_at                                                    GFAP\*        glial fibrillary acidic protein                                                         7.0            5.2            3.3               0
  CfaAff × 0.9311.1.S1_s\_at                                                GMFG          "glia maturation factor, gamma"                                                         9.2            7.9            2.5               0
  Cfa.19828.1.S1_at                                                         LOC475881     similar to Neuronal cell adhesion molecule precursor (Nr-CAM)                           9.5            8.5            2.0               0
  \*Cfa.10277.1.S1_at                                                       S100A1\*      S100 calcium binding protein A1                                                         10.9           9.6            2.3               0

Asterisks indicate that elevated levels for this gene were detected by more than one probe set. Expression levels and fold change values are given as log^2^ units.

Interestingly a plot of the average detected gene expression changes versus the p-value associated with each measurement reveals a marked asymmetry between transcripts with reduced expression and those with elevated expression ([Figure 2](#f2){ref-type="fig"}). While transcripts detected at lower levels in the glaucomatous retina show a good correlation between the degree of expression change and associated p-value, genes with higher average expression in glaucoma are frequently associated with non-significant p-values. This is true even for genes with comparatively large changes in average expression levels. These higher p-values are typically the result of a large standard deviation between the values in the glaucoma group. These data indicate that the factors causing lower gene expression are largely similar between the individuals evaluated, whereas glaucomatous events resulting in elevated transcript levels are much less uniform.

![Volcano plot of the gene expression changes in the canine glaucomatous retina. Negative expression changes denote transcripts detected at reduced levels in glaucomatous eyes. This plot also represents all expressed genes, including those with less than twofold expression changes. Vertical bars represent a twofold expression change. Probability values were derived by Student's *t*-test.](mv-v16-2092-f2){#f2}

To test the accuracy and reproducibility of the Gene chip data we also sought to confirm the observed gene expression differences between glaucomatous and normal retinas using quantitative PCR. Clearly, verification of all gene changes is impractical and consequently only a subset of genes was selected. In the selection of these genes we avoided those with already well described glaucoma related expression changes, such as *GFAP* and complement components \[[@r8]-[@r12]\], and focused instead on less well characterized genes ([Figure 3](#f3){ref-type="fig"}). Our RT--PCR data indicate that expression levels vary considerably among the nine affected animals evaluated for this part of the study. However, statistically significantly elevated (p\<0.05 by *t*-test) levels of colony stimulating factor 1 receptor (*CSF1R*), glia maturation factor gamma (*GMFG*), neuronal cell adhesion molecule (*NRCAM*), neurotrophin 3 (*NTF3*), Calgizzarin (*S100A1*), TNF receptor 1 (*TNFRSF1A*) and TNF receptor 14 (*TNFRSF14*) were confirmed.

![Verification of selected expression changes by quantitative PCR. Elevated expression could be confirmed for colony stimulating factor 1 receptor (*CSF1R*), glia maturation factor gamma (*GMFG*), neuronal cell adhesion molecule (*NRCAM*), neurotrophin3 (*NTR3*), Calgizzarin (*S100A1*), TNF receptor 1 (*TNFRSF1A*), and TNF receptor 14 (*TNFRSF14*). Error bars signify standard error.](mv-v16-2092-f3){#f3}

Immunohistochemical evaluation
------------------------------

Our molecular findings, in accord with previously published studies, suggest that modulation of TNF alpha and its receptors is correlated to the development of glaucoma. Morphometric analyses performed on retinas from of healthy and glaucomatous dogs using anti-TNF antibodies demonstrated increased immunereactivity in the glaucomatous retina ([Figure 4A,B](#f4){ref-type="fig"}). Quantitation of the observed signal demonstrated a significant increase in TNF labeling both in the central and the peripheral retina ([Figure 5A](#f5){ref-type="fig"}).

![Digitalized images of immunohistochemistry based protein expression, which were used for quantification purposes. Increased TNF alpha expression was detected in glaucomatous eyes (**B**), predominantly in the nerve fiber layer, when compared to the control eyes (**A**). TNF alpha receptor 1 protein expression had similar appearance in control and glaucomatous eyes (**C**, **D**). TNF alpha receptor 2 protein expression was higher in glaucomatous eyes (**F**) when compared to control eyes (**E**).](mv-v16-2092-f4){#f4}

![Quantitative analysis of TNF, TNFR1, and TNFR2 expression in the glaucomatous retina. Quantitative analysis of TNFa (**A**), TNF receptor 1 (**B**), and TNF receptor 2 (**C**) immune reactivity in the central and peripheral retina of dogs with and without glaucoma. Statistical analyses reveal significantly higher TNF-alpha (**A**) and TNF-alpha receptor 2 (**C**) expression in glaucomatous eyes, when compared to control eyes. There was no significant difference in TNF alpha receptor 2 expression between control and glaucomatous eyes (**B**).](mv-v16-2092-f5){#f5}

Similar changes were observed for TNF receptor 2 (TNFR2). Immunoreactivity for this molecule is significantly increased in the peripheral and central retina of glaucomatous eyes when compared to normal eyes ([Figure 4E,F](#f4){ref-type="fig"} and [Figure 5C](#f5){ref-type="fig"}). In contrast, our data suggest that expression levels for TNF receptor 1 (TNFR1) remain unchanged in the glaucomatous retina ([Figure 4C,D](#f4){ref-type="fig"} and [Figure 5B](#f5){ref-type="fig"}). The finding that overall TNFR1 immunoreactivity remains relatively unchanged contrasts with our data suggesting elevated mRNA levels of the TNFR1 gene (*TNFRSF1A*) in glaucoma.

The pronounced appearance of MHC class I and inflammation related gene transcripts could be interpreted as indicative of leukocyte infiltration into the canine glaucomatous retina. Immunohistochemical analyses using sagittal sections of several canine glaucomatous retinas and antibodies directed against the T- and B- cell antigens CD3 and CD79 did not reveal immunopositive cells in the evaluated samples ([Figure 6A](#f6){ref-type="fig"}). CD3 positive cells could readily be detected in a tissue sample of canine optic neuritis, used here as a positive control ([Figure 6B](#f6){ref-type="fig"}), and were occasionally observed in the perivascular space in glaucoma retinas. These findings suggest that leukocyte infiltration into the retina of glaucomatous dogs it is, at most, a rare event.

![Immunohistochemical detection of CD3. CD3 positive cells are not apparent in the canine glaucomatous retina (left). In contrast, CD3 positive cells can easily be detected in optic nerve sections of a canine patient with optic neuritis (positive control). Note labeled cells in the perivascular space of the optic nerve (arrows). ONL-outer nuclear layer, INL-inner nuclear layer, NFL -- nerve fiber layer.](mv-v16-2092-f6){#f6}

Detection of serum autoantibodies to retinal antigens
-----------------------------------------------------

Despite the apparent paucity of CD3/CD79 positive cells, it was conceivable that canine glaucoma may result in the formation of autoantibodies directed against retinal antigens. To determine if this does indeed occur, we incubated western blots of retinal protein extracts with serum obtained from seven dogs with moderate to advanced glaucoma and ten healthy control animals ([Figure 7](#f7){ref-type="fig"}). While minor immune reactivity can be observed in all samples, the majority of the serum obtained from dogs with glaucoma reacts with retinal proteins more vigorously than that obtained from healthy control dogs. It is noteworthy that the samples with the most pronounced immunoreactivity were derived from dogs with advanced glaucoma. A general pattern of labeled bands is not apparent, rather it appears that each individual displays immunereactivity to a specific subset of molecules. In the majority of cases the labeled molecules do not react with purified Recoverin, α-enolase, or crystallins, suggesting that these proteins are not major autoantigens in dogs with glaucoma.

![Western blotting analysis of autoantibodies present in sera of dogs with glaucoma and in sera of control healthy dog sera. Sera from dogs with glaucoma are labeled from 1 to 7; control dog sera are labeled as "control dog sera," Lanes R- recoverin, E -- enolase, C - crystalline-μ are immunostained with antibodies specifically directed against these molecules. N -- negative control, M -- molecular weight markers.](mv-v16-2092-f7){#f7}

Discussion
==========

In this study we characterize the molecular events that are associated with advanced glaucomatous degeneration of the retina in dogs. These data are the first to describe changes in the gene expression pattern and immunological consequences in a species with large eyes and spontaneously occurring chronic elevation of IOP. One shortcoming of this study is that the control and glaucoma groups were are not closely matched in age and are derived from a variety of breeds. These factors will likely influence the expression levels of some genes, but the overall similarity in canine retinal morphology and function suggest that these differences between the two groups will be relatively minor.

In accordance with previous studies, our data demonstrate that advanced glaucomatous retinopathy is associated with pronounced changes in the retinal gene expression pattern. Among genes with elevated expression levels in glaucoma, a preponderance of genes mediating various aspects of a neuroinflammatory response was striking. Prominent functional categories of genes with elevated expression in glaucoma include antigen presentation, complement activation, lysosomal and proteasome activity, and acute phase proteins. In addition, numerous genes with a function in apoptosis and inflammation signaling are more abundant in retinas with glaucoma than in those without. It must be noted that many of the identified genes with altered expression levels are associated with several biologic function, thus inclusion in one functional category does not exclude a gene's involvement in additional molecular pathways.

Our analyses also indicate that glaucoma leads to lower expression levels for a large number of genes, including various neurofilaments, synucleins, and neuregulin 1. Functionally, no particular group of molecules appears to be disproportionally affected. Rather, we detected decreased expression levels of a large number of functional categories, including neuronal development and maintenance, cell adhesion, calcium transport and binding, transcriptional regulation, synaptic transmission, and many others. Reduced mRNA levels of individual genes could result from transcriptional control mechanisms. Alternatively, reduced levels of a specific mRNA in a tissue comprised from several cell types may be related to loss of the cell type that synthesizes the majority of this mRNA. Genes such as *STMN2*, *NEFH*, *NRG1*, *ELAV2*, and *SNCG* appear to be primarily expressed by RGC \[[@r13]-[@r15]\] and the decrease of their transcript levels is conceivably due to the loss of RGC and, perhaps, amacrine cells \[[@r16],[@r17]\] in the glaucomatous retina and may not represent transcriptional regulation.

Decreased expression levels were also detected for several photoreceptor cell specific genes in the glaucomatous retina. Whether photoreceptor cell loss or functional decline is a feature of advanced glaucoma has been extensively debated \[[@r18]-[@r21]\]. In this study significantly decreased expression levels are only observed for a small number of photoreceptor cell specific genes, while most of photoreceptor cell associated transcripts are present at similar or only mildly reduced levels (i.e., less than the twofold cut off value employed) suggesting only a minor effect of glaucoma on the transcriptional activity of photoreceptor cells in the dog.

The systematic comparison of findings in this study to those presented previously by other investigators is not straightforward due to the different formats of gene arrays used, selection of genes represented on each array, incomplete identification of orthologs between animal species, and the stage of disease investigated. Previous studies had observed a striking decrease in the expression levels for several crystallin genes in rodent models of glaucoma \[[@r3]-[@r5],[@r22]\]. Although probes for these molecules are present on the gene chips used in this study, our data do not mirror these findings. Reduced synthesis of retinal crystallins could represent a rodent specific response to elevated IOP. However, several studies have demonstrated that expression levels for various crystallin genes decrease quickly after induction of ocular hypertension, but return to normal levels 2 to 3 weeks later \[[@r3],[@r22]\]. Thus, decreased expression of crystallins may reflect an early, transient event in glaucoma pathology.

Our findings largely agree with previously published reports that clearly demonstrated the involvement of the complement system in the pathophysiology of glaucoma and noted the expression of other inflammation-related molecules by retinal cells \[[@r3]-[@r5],[@r8],[@r23],[@r24]\]. While some studies have suggested that a breakdown of the blood brain barrier may occur in the eyes of dogs with severe glaucoma \[[@r25],[@r26]\] our own immunohistochemical data suggest that CD3 or CD79 positive cells in canine glaucoma occur, at most, infrequently. In contrast, most hybridization signals of inflammation associated transcripts are quite strong, indicating that these gene products are abundant in the retina of dogs with glaucoma and thus likely originate from a cell type that is relatively common in this tissue. Micro- and macroglia constitute a sizable share of the retinal cell population and several studies have demonstrated that glia are capable of transcribing several of the inflammation-associated genes detected at elevated levels in this study, e.g., AIF1, CXCL12, and MHC class 2 molecules \[[@r27]-[@r30]\]. Retinal glia may also contribute to the observed synthesis of inflammatory molecules, e.g., both CXCL10 and CXCL16 are produced by reactive astrocytes \[[@r31],[@r32]\].

An important function of glia is to phagocytose foreign particles or cell debris, a process activated by the *LGALS3* gene \[[@r33]\]. Macrophages that have ingested apoptotic cells appear to inhibit the production of proinflammatory molecules \[[@r34]\] and is possible that retinal microglia are capable of mediating a similar repression of some proinflammatory stimuli after phagocytosis of RGC debris. In that regard, the increased expression of the *TREM2* receptor in the glaucomatous retina is noteworthy, as its interaction with its ligands appears to mediate inhibition of inflammation and stimulation of antigen presentation \[[@r35]\].

We propose that the massive retinal inflammation and antigen presentation responses described here represent late events in the pathophysiology of glaucoma. Increased expression of individual inflammation-related genes has been reported previously in studies that evaluated earlier stages of glaucomatous damage. While this neuroinflammatory response was not observed to the degree seen here data presented by Ahmed et al. suggest progressively increasing expression levels of several immune response molecules during the development of the disease \[[@r3]\].

Our data suggest that the anti-inflammatory mechanisms that protect the retina in early glaucoma can eventually fail, leading to the development of autoantibodies in many glaucomatous dogs. Although the number of examined samples is relatively small, the fact that all analyzed serum samples from dogs with glaucoma display immunereactivity against distinct antigens, suggests that glaucoma is not initiated by an immune response to specific retinal antigens. Rather it appears likely that the variety of immunoreactive molecules is due to exposure of numerous epitopes during the rapid neuronal cell death of the retina. Consequently the development of anti-retinal antibodies may be secondary to the degeneration of RGC. Never-the-less, exposure to serum antibodies directed against retinal antigens has been shown to induce RGC loss that resembles glaucoma \[[@r36],[@r37]\]. Thus it is conceivable that once an immune response has occurred, it will further accelerate vision loss in an IOP independent mechanism.

The relevance of our findings to human disease remains to be determined. Glaucoma in dogs often presents with comparatively high intraocular pressure, introducing the possibility that ischemic events to the inner retina contribute to the pathophysiology of glaucoma in this species more than they do in humans. It is well documented that retinal ischemia leads to increased vascular permeability (reviewed in \[[@r38]\]) and given the chronic nature of IOP elevation in glaucoma it is conceivable that even a rare presence of T-cells could over time result in an antigenic response in this species. The intraocular pressure in human patients receiving ophthalmic care is typically much lower than that in glaucomatous dogs and leukocyte infiltration of the retina does not appear to be a feature of human glaucoma. Yet several reports have suggested the presence of autoantibodies against retinal epitopes in the serum of some glaucoma patients \[[@r39]-[@r41]\]. Whether those glaucoma patients with detectable autoimmune titers to the retina share a genetic predisposition toward a vigorous immune response or exhibit other unifying features has, to our knowledge, not been thoroughly investigated.

Regardless of the potential role of an adaptive immune response in glaucoma, data from numerous studies indicate that neuroinflammatory events do occur as a consequence of neuronal degeneration in glaucoma. Consequently it is conceivable that therapeutic modulation of the neuroinflammatory response may be a beneficial augmentation to IOP lowering therapy in glaucoma.
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